Neurocrine Biosciences Inc
$ 163.41
2.25%
07 Aug - close price
- Market Cap 16,245,574,000 USD
- Current Price $ 163.41
- High / Low $ 164.76 / 159.68
- Stock P/E 23.57
- Book Value 33.87
- EPS 6.78
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.12 %
- ROE 0.22 %
- 52 Week High 186.12
- 52 Week Low 122.14
About
Neurocrine Biosciences, Inc., a biopharmaceutical company, discovers, develops, and markets pharmaceutical products for the treatment of neurological, endocrine, and psychiatric diseases and disorders in the United States. The company is headquartered in San Diego, California.
Analyst Target Price
$213.13
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-07-30 | 2026-05-05 | 2026-02-11 | 2025-10-28 | 2025-07-30 | 2025-05-05 | 2025-02-06 | 2024-10-30 | 2024-08-01 | 2024-05-01 | 2024-02-07 | 2023-10-31 |
| Reported EPS | 2.36 | 1.94 | 1.88 | 2.17 | 1.65 | 0.7 | 1.69 | 1.81 | 1.63 | 1.2 | 1.54 | 1.54 |
| Estimated EPS | 1.88 | 1.7 | 2.3 | 2.07 | 1.5 | 1.09 | 1.93 | 1.82 | 1.53 | 1.29 | 1.51 | 1.33 |
| Surprise | 0.48 | 0.24 | -0.42 | 0.1 | 0.15 | -0.39 | -0.24 | -0.01 | 0.1 | -0.09 | 0.03 | 0.21 |
| Surprise Percentage | 25.5319% | 14.1176% | -18.2609% | 4.8309% | 10% | -35.7798% | -12.4352% | -0.5495% | 6.5359% | -6.9767% | 1.9868% | 15.7895% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: NBIX
2026-08-05 21:10:13
Jude Onyia, Chief Scientific Officer of Neurocrine Biosciences (NBIX), made a bona fide gift of 2,409 shares of common stock effective August 4, 2026. This transaction was a charitable contribution, not a market sale, and no value was received for the shares. After this gift, Onyia directly holds 20,996 shares of NBIX common stock.
2026-08-05 18:41:57
Neurocrine Biosciences (NBIX) is presented as a compelling value stock due to its strong valuation score, profitability, and growth prospects despite trading at a higher-than-average P/E. The company boasts excellent financial health, a debt-free balance sheet, and impressive historical and projected EPS and revenue growth. While risks such as pipeline uncertainties and lack of dividends exist, NBIX's fundamentals suggest it's a solid opportunity for value-oriented investors.
2026-08-03 15:10:46
H.C. Wainwright has reiterated a Buy rating and a $215.00 price target for Neurocrine Biosciences (NASDAQ:NBIX), citing significant progress in its drug pipeline. The company affirmed upcoming Phase 3 data for osavampator in major depressive disorder and direclidine in schizophrenia, both of which showed promising results in earlier trials. This comes after strong second-quarter 2026 financial results, with earnings and revenue exceeding expectations, leading several other analyst firms to raise their price targets for NBIX.
2026-08-03 15:10:46
Canaccord Genuity raised its price target on Neurocrine Biosciences (NASDAQ:NBIX) to $210 from $200, maintaining a Buy rating after the company's strong Q2 results. Sales
2026-08-03 12:12:59
H.C. Wainwright has reaffirmed its Buy rating and $215.00 price target for Neurocrine Biosciences Inc. (NASDAQ: NBIX), citing the company's strong pipeline progress and financial performance. The company reported significant revenue growth and provided updates on its clinical trials for osavampator and direclidine, which are showing promising results for major depressive disorder and schizophrenia, respectively. This positive outlook is further supported by Neurocrine's impressive Q2 2026 earnings and increased guidance for Ingrezza sales.
2026-08-03 11:12:59
Canaccord Genuity has increased its price target for Neurocrine Biosciences (NBIX) to $210 from $200, maintaining a Buy rating, after the company reported strong second-quarter results. Sales for its treatments Ingrezza and Crenessity significantly exceeded analyst estimates, contributing to a 34% revenue growth over the past twelve months. The firm views Neurocrine as undervalued, with further catalysts expected from its pipeline in 2027 and beyond.
